

DAFTAR PUSTAKA

- Abrahamsson, J. 2012. *NOPHO-DBH AML Protocol: Research study for treatment of children and adolescents with acute myeloid leukaemia 0-18 years*. NOPHO-DBH AML 2012 protocol v2.1. Children's Cancer Centre Queen Silvias Childrens and Adolescents Hospital 416 85 Gothenburg, Sweden
- Annie, I., Amjad A., Agha, M., Raptis, A., Hou, J.Z. 2016. Mitrozantrone and etoposide for the treatment of acute myeloid leukemia patients in first relapse. *Oncology research*, 24: 73-80.
- Banavali, S., Goyal, L., Padhye, B., Arora, B., Bhagwat, R. 2005. Novel Therapeutic Approach Yields Excellent Results in Minimally Differentiated Acute Myeloid Leukemia (AML-M0): Time To Think out of the Box. *India Blood*, 106 (11): 4615.
- Bansal, D., Davidson, A., Supriyadi, E., Njuguna, F., Ribeiro, R.C., Kaspers, G.J.L. 2019. SIOP PODC adapted risk stratification and treatment guidelines: recommendations for acute myeloid leukemia in resource-limited settings. *Pediatr Blood Cancer*, e28087.
- Bleibel, W.K., Duan, S., Huang, R.S., Kistner, E.O., Shukia, S.J. 2009. Identification of genomic regions contributing to etoposide-induced cytotoxicity. *Hum Genet*, 125(2):173-180.
- Caroline, A.H., Torkildson, J.C. 2021. *Acute Leukemias: Handbook of Pediatric Hematology and Oncology*. Wiley-Blackwell. Third Edition.
- Chatterjee, K., Zhang, J., Honbo, N., Karliner, J.S. 2010. Doxorubicin cardiomyopathy. *Cardiology*, 115: 155-162.
- Chessells, J.M., Richards, S. M., Bailey, J.S., Lilleyman and Eden, O.B. 1995. Gender and treatment outcome in childhood lymphoblastic leukemia: report from the MRC UKALL trials. *British J of Hematology*, 89: 364-372.

Cohen, N.A., Zeller, B., Abrahamsson, J. Navarrod, J.M. Cheuke, D. 2022. Supportive care in pediatric acute myeloid leukemia: Expert-based recommendations of the NOPHO-DB-SHIP consortium. *Expert review of anticancer therapy*, 22(11): 1183–1196.

Devlin, L. and Morrison, P.J. 2004. Accuracy of the clinical diagnosis of Down Syndrome. *The Ulster Medical Journal*, 73: 4-12

Elgarten, C.W and Aplenc, R. 2019. Pediatric acute myeloid leukemia: updates on biology, risk stratification and therapy. *Curr Opin Pediatr*, 31

Francia, R.D., Crisci, S., Monaco, A.D., Cafiero, C., Re, A., Laccarino, G., Fillipi, R.D., Frigeri, F., Corazelli, G., Micera, A. 2021. Response and toxicity to cytarabine therapy in leukemia and lymphoma: from dose puzzle to pharmacogenomic biomarkers. *Cancer*, 13: 966

Gao, A., Zhang, L., Zhong, D. 2023. Chemotherapy-induced thrombocytopenia: literature review. *Discover Oncology*, 14: 10.

Ghafoor, T., Khalil, S., Farah, T., Ahmed, S., Sharif, I. 2020. Prognostic faktor in childhood Acute Myeloid Leukemia; experience from a developing country. *Cancer reports*, 3: 259.

Guo, Y., Wang, W., Sun, H., A systematic review and meta-analysis on the risk faktors of acute myeloid leukemia. 2022. *Transl Cancer Res*, 11(4): 796-804.

Gupta, S., Bonila, M., Valverde, P., Fu, L., Howard S.C., Ribeiro, R.C., Sung, L. 2011. Treatment-related mortality in children with acute myeloid leukemia in Central America: incidence, timing and predictors. *European journal of cancer*, 48(9):1363-1369.

Hao, T.K., Ha, C.V., Son, N.H., Hiep, P.N. 2020. Long term outcome of childhood acute myeloid leukemia: a 10-year retrospective cohort study. *Pediatrics Report*, 12: 84-86.

Hayon, I.L. 2014. Signal, transduction, and the hematopoietic stem cell. *Rambam Maimonides Med J*, 5: 4.

Hernandez, E.J., Gonzales, M.T.D., Galindo, J.A., Zarate, M.E.M., Mendez, V.C.B., Garcia, A.B. 2015. Survival of Mexican children with acute myeloid leukaemia who received early intensification chemotherapy and an autologous transplant. *BioMed Research Int*, ID 940278.

Hossain MJ, Xie L, Caywood EH 2015. Prognostic factors of childhood and adolescent acute myeloid leukemia (LMA) survival: evidence from four decades of US population data. *Cancer Epidemiol*, 3: 341–345.

Karruli, A., Catalini, C., Amore, C., Foglia, F., Mari, F. 2023. . Evidence-Based Treatment of *Pseudomonas aeruginosa* Infections: A Critical Reappraisal. *Antibiotics*, 12: 399.

Kobayashi, K., Ratain, M. J. 1994. Pharmacodynamics and long-term toxicity of etoposide. *Cancer Chemother Pharmacol*, 34: 64-68.

Knoble, N.B., Alderfer, M., Hossain, M.J. 2016. Socioeconomic status (SES) and childhood acute myeloid leukemia (LMA) mortality. *Cancer Epidemiol*, 44:101-108.

Kristian, R. 2012. *Deciphering the pathogenesis of acute myeloid leukemia*. Doctoral thesis. Faculty of Medicine. Division of Molecular Medicine and Gene Therapy. Lund University.

Leoni, S. Ciolli, S. Palriarchi, M. Morfini, P. Rossi Ferrini. 1990. Etoposide in Remission Induction of Adult Acute Myeloid Leukemia. *Acta Haematol*, 83: 82-85.

Licht, J.D and Sternberg, D.W. 2005. The molecular pathology of acute myeloid leukemia. *Hematology*. American Society of Hematology.

Lins, M.M., Mello, M.J.G., Ribeiro, R.C., Camargo, B.D., Fatima, M.D *et al.* 2019. Survival and risk factors for mortality in pediatrics patients with acute myeloid

leukemia in a single reference center in low middle income country. *Annals of Hematology*, 98: 1403-1411.

Mamo, W., Moges, A., Yesuf, A.A., Mohamedsaid, A., Arega, G. 2024. Treatment outcomes of pediatrics acute myeloid leukemia (AML) and associated factors in the country's tertiary referral hospital, Ethiopia. *BMC Cancer*, 24: 640.

Marconi, G., Talami, A., Abbenante, M. C., Sartor, S., Parisi, S. 2020. MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia. *Eur J Haematol*, 105: 47–55.

Morais, V., Souza, M.V., Silva, K.A., Santiago, P., Lorenzoni, M.C., Lorea, C.F. Junior, C.G.C., Taniguchi, A.N.R., Schrer, F.F., Michalowski, M.B., Daudt, L.E. 2020. Epidemiological evaluation and survival of children with acute myeloid leukemia. *J.j ped.* <https://doi.org/10.1016/j.jpmed.2020.02.003>.

Nadhira, F., Supriyadi, E., Lazuardi, L. 2019. Perbandingan terapi protokol nasional dengan protokol lainnya pada pasien leukemia mieloblastik akut anak di RSUP Dr Sardjito 2007-2016. Perpustakaan Universitas Gadjah Mada. Etd.repository.ugm.ac.id/penelitian/detail/173841.

Patto de Goes, L.S., Lopes, R.I., Campos, O.H.A., Oliviera, L.C.N., Anna, A.C., Oglio, M.F., Srougi, M. 2014. Recurrence of acute myeloid leukemia in cryptorchid testis: case report. *Einstein*, 12(1): 109-111.

Razzouk, B.I., Estey, E., Pounds, S.B., Lensing, S.L., Pierce, S., *et al.* 2004. Effect of age on prognosis in childhood acute myeloid leukemia. *Blood*, 104(11): 1064.

Sastroasmoro, S., Ismael, S. 2011. Dasar-dasar metodologi penelitian klinis. Edisi ke-4. Sagung Seto. Jakarta.

Schmidt, M.P., Colita, A., Ivanov, A.V., Coriu, D., Miron, I.C. 2021. Outcomes of patients with Down Syndrome and acute leukemia. *Medicine*, 100: 40.

Schulpen, M., Visser, O., Ardine, M.J., Reedijk, A., Leontien, *et al.* 2021. Significant improvement in survival of advanced stage childhood and young adolescent cancer in Netherlands since 1990s. *European Journal of Cancer*, 157: 81e93

Sjakti, H.K., Gatot, D., Widiastuti, E. 2012. Hasil pengobatan leukemia mieloblastik akut pada anak. *Sari Pediatri*, 14: no 1.

Sjakti, H.K., Windiastuti, W. 2012. Pola infeksi pada leukemia mieloblastik akut pada anak. *Sari Pediatri*, vol 13: no 6.

Smith, I.E., Clink, H., Gerken, M.E., McElwain, T.J. VP 16-213 in acute myelogenous leukemia. 1976. *Postgraduate medical journal*, 52: 66-70.

Sung, L., Aplenc, R., Alonzo, T.A. 2012. Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children's Oncology Group. *Haematologica*, 97(11).

Supriyadi, E., Purwanto, I., Widjajanto, P.H. 2013. Terapi leukemia mieloblastik akut anak: protocol Ara-C, doxorubicine dan etoposide (ADE) vs modifikasi Nordic Society of Pediatric Hematology and Oncology (m-NOPHO). *Sari Pediatri*, 14: no 6.

Steffen, B., Tidow, C.M., Schwable, J., Berdel, W.E., Serve, H. 2004. The molecular pathogenesis of acute myeloblastic leukemia. *Critical reviews in Oncology/Hematology*, 56: 195-221.

Verschuur, A.C. 2004. Acute myelomonocytic leukemia. *Orphanet Encyclopedia*, 1-5.

Weelderen, R.E.V., Njuguna, F., Klein, K., Mostert, S., Kaspers, G.J.L. 2021. Outcomes of pediatric acute myeloid leukemia treatment in Western Kenya. *Cancer Reports*, 5: e1576.

Weelderen, R.E.V., Klein, K., Natawidjaja, M.D., Vries, R.D., Kaspers, G.J.L. 2021. Outcome of pediatrics acute myeloid leukemia (LMA) in low- and middle-

income countries: a systematic review of the literature, *Expert Review of Anticancer Therapy*, 21: 765-780.

Wiernik, P.H., Sun, Z., Cripe, L.D., Rowe, J.M., Fernandez, H.F., Luger, S.M., Lazarus, H.M., Paietta, E.M., Tallman, M.S., Mark, R., Litzow. 2021. Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukemia. *Br.J. Haematol*, 194(2): 309-318.

Yu, V. W., and Scadden, D. T. 2016. Hematopoietic Stem Cell and Its Bone Marrow Niche. *Curr. Topics Develop. Biol.* 118, 21–44. doi: 10.1016/bs.ctdb.2016.01.009

Zhang, W., Gou, P., Dupret, J.M., Chomienne, C., Lima, FR. 2021. Etoposide, an anticancer drug involved in therapy-related secondary leukemia: enzymes at play. *Translational Oncology*, 14: 101169.

Zwaan CM, Kolb EA, Reinhardt D, Abrahamsson J, Adachi S, Aplenc R, De Bont ESJM, De Moerloose B, Dworzak M, Gibson BES, Hasle H, Leverger G, Locatelli F, Ragu C, Ribeiro RC, Rizzari C, Rubnitz JE, Smith OP, Sung L, Tomizawa D, Van Den Heuvel-Eibrink MM, Creutzig U, Kaspers GJL. 2015. Collaborative efforts driving Progress in pediatric acute myeloid leukemia. *J Clin Oncol*, 33: 2949–2962.